HighPoint Advisor Group LLC Makes New $509,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

HighPoint Advisor Group LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 16,308 shares of the company’s stock, valued at approximately $509,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Ethic Inc. lifted its position in Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Teva Pharmaceutical Industries by 3.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after purchasing an additional 379 shares in the last quarter. Howard Bailey Securities LLC boosted its holdings in Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock valued at $292,000 after purchasing an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. boosted its holdings in Teva Pharmaceutical Industries by 1.6% in the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after purchasing an additional 540 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $35.33 on Friday. The business’s 50 day simple moving average is $31.51 and its 200-day simple moving average is $30.40. The firm has a market capitalization of $40.62 billion, a price-to-earnings ratio of 26.56, a price-to-earnings-growth ratio of 3.51 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. The trade was a 34.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 1,127,018 shares of company stock worth $37,298,712. Corporate insiders own 0.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Truist Financial lifted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.